Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:3:499-513.
Epub 2009 Dec 29.

New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents

Ara Metjian  1 , Charles S Abrams
Affiliations

New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents

Ara Metjian et al. Biologics. 2009.

Abstract

Decades of basic science and clinical research have led to an increased understanding of the pathophysiology of immune thrombocytopenic purpura (ITP), the processes underlying thrombopoiesis, and the treatment of chronic ITP. Now, new agents are available to treat ITP in a nonimmunosuppressive fashion. Lessons learned from the clinical trials of recombinant human thrombopoietin (TPO) have led to the development of a novel class of compounds: nonimmunogenic agonists of the thrombopoietin receptor. Representing the first nonimmunosuppressive agents to treat chronic refractory ITP in decades, medications such as romiplostim and eltrombopag were recently approved by the US Food and Drug Administration. These new agents offer physicians a new tool for treating difficult cases of ITP in their medical armamentarium. Additional TPO mimetics are also being developed that show promise in vitro, and await future development.

Keywords: eltrombopag; immune-mediated thrombocytopenia; romiplostim; thrombocytopenia; thrombopoietin; thrombopoietin receptor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of romiplostim.
Figure 2
Figure 2
Chemical structure of eltrombopag.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3–40. - PubMed
    1. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574–596. - PubMed
    1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995–1008. - PubMed
    1. Whipple A. Splenectomy as a therapeutic measure in thrombocytopenic purpura hæmorrhagica. Surg Gynecol Obstetr. 1926;42:329–341.
    1. Meyers MMS, Bethell FH. Administration of ACTH in hypersplenic syndromes. J Lab Clin Med. 1950;36(6):965–966. - PubMed

LinkOut - more resources